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Inflammatory Bowel disease (IBD) is traditionally divided into Crohn’s disease (CD) and
ulcerative colitis (UC). UC is a relapsing non-transmural inflammatory disease that is
restricted to the colon and is characterized by flare-ups of bloody diarrhea. CD is a
chronic, segmental localized granulomatous disease that can affect any part of the entire
gastrointestinal tract. Ileo-anal pouch is a procedure restoring functionality of the rectum
after a colectomy. IBD is a multifactorial disease and flares of IBD are probably triggered
by changes in the intestinal microbiota followed by an abnormal immune response. In this
study, we aim to analyze the intestinal bacterial diversity in IBD patients during various
stages of disease compared with healthy controls. Permission for human experiments
and recruitment of participants was obtained from the Ethic Committee for Copenhagen
County hospitals (Permission no. KA-03019, Permission no. KA-20060159). Stools
from 26 healthy controls, 42CD, 38 UC and 18 pouch patients were collected. Stool
DNA extraction was performed using Qiagen, DNA mini stool kit Denmark. DGGE-PCR
amplifying the V2-V3 region of 16S-rDNA gene of the bacteria was amplified by universal
primers HDA1 and HDA2. Analysis of DGGE was performed blinded using BioNumerics
version 7.5. After normalization, a DGGE gel band matching was performed. The
similarities between profiles were calculated with a ranked Pearson correlation coefficient
based on the band matching results using band intensities. Simpson’s index of diversity
and Pielou’s species evenness were calculated. Based on the Shannon Diversity Index,
UC patients had lower species diversity and bacterial evenness in comparison to healthy
persons, p < 0.05. However, only CD and disease pouch patients had lower species
diversity compared to those with inactive disease and healthy controls. Well-functioning
pouch patients had decreased species evenness in comparison to diseased pouch
patients and control group. During the active disease stage in CD and pouch, the patients
have a low bacterial diversity in their gut when compared to the inactive stage. In UC
patients, a generally low diversity was observed at all stages of the disease compared to
healthy controls.
Keywords: inflammatory bowel disease, ulcerative colitis, crohn’s disease, intestinal microbiome, ileo-anal pouch,
dysbiosis, shannon diversity index, pielou index
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INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) are the
two main forms of inflammatory bowel disease (IBD),
characterized by periods of remission and relapses (1). CD
is a chronic inflammatory condition that involves any part of
the gastrointestinal tract, while UC is a chronic inflammation
localized in the colon (1). The etiology of IBD is still unknown,
but many studies indicate a combination of nutrition (2, 3),
intestinal dysbacteriosis (4, 5), and abnormal immune response
(6–8). During the last two decades, the focus has been on the role
of microbiota as a driver of the inflammatory process in IBD.
One theory suggests that living in an industrialized country
with high hygiene standards lowers the exposure to complex
microbial communities during the development of the immune
system. As a result, the immune system is less able to tolerate
exposure to environments rich on microbiota resulting in an
inappropriate immune activation (6). Humans live in a symbiotic
relationship with the gut microbiome, in which humans provide
the ideal environment for the microbiota to flourish and bacteria
in return ferment the food carbohydrates to short fatty acids,
synthesize certain vitamins and degrade dietary oxalates (2–5).
Studies show that IBD with active disease is strongly
associated with an overall increased prevalence of proteobacteria
(9, 10) and drop in intestinal species richness, more specifically
a significant drop in firmicutes (11, 12), Enterobacteriaceae,
Bacteroidales, and Clostridiales (13) of Clades IV and XIVa (13).
Decreased prevalence of butyrate-producing bacteria such as
Clostridiales species in the gut explains the decreased amount of
short chain fatty acids in fecal samples from IBD patients (14, 15).
Butyrate serves as a major source of energy for colonic epithelial
cells (16) and as an inhibitor of pro-inflammatory cytokine
expression in the intestinal mucosa through a mechanism
that involves hyper-acetylation of histones and suppression of
NF-κB signaling (17). Butyrate reinforces the mucosal barrier
by inducing production of mucin and antimicrobial peptides,
and by strengthening epithelial barrier integrity through directly
increasing the expression of tight junction proteins (18). More
recent studies indicate a link between IBD and a decreased
prevalence of butyrate-producing Faecalibacterium prausnitzii
(firmicute), belonging to Clostridia cluster IV species (19, 20),
increased prevalence of adherent-invasive E. coli (AIEC) in
ileal CD (21, 22) and increased prevalence of E. coli with
extra intestinal pathogenic E. coli properties (23–25). It has
been shown that fecal microbiota transplantation (FMT) is an
effective treatment of UC, indicating that colon microbiota play
an essential role in UC (26). A subdivision of IBD into three
phenotypes as ileal CD, colonic CD, and UC according to genetic
composition has been suggested (27).
In this study, the goal was to investigate intestinal bacterial
diversity in IBD patients with active and inactive disease
compared to healthy controls, using PCR amplification of regions
Abbreviations: IBD, Inflammatory Bowel Disease; UC, Ulcerative colitis; UCA,
Ulcerative colitis with active disease; UCI, Ulcerative colitis with inactive disease;
CD, Crohn’s disease; CDA, Crohn’s with active disease; CDI, Crohn’s with inactive
disease; PA, Disease pouch; PI, well-functioning pouch.
of the 16S ribosomal RNA gene and Denaturing Gradient Gel
Electrophoresis (DGGE).
MATERIAL AND METHODS
This study included 97 adult IBD patients with a previously
confirmed IBD diagnosis and 31 healthy controls, aged from 25
to 86 and 18 to 67 years, respectively. Symptom scores, stool
and blood samples were collected from 38 patients with UC, 15
females and 23 males, 20 with active (UCA) and 18 with inactive
(UCI) disease, 41 patients with Crohn’s disease, 28 females and 13
males, 21 with active (CDA) and 20 with inactive (CDI) disease,
18 patients with an ileo-anal pouch (UC patients who underwent
surgical treatment), 8 females and 10males, including 7 pouchitis
(PA), and 11 well-functioning pouch (PI) patients. The disease
activity was measured with the Simple Clinical Colitis Activity
Index (SCCAI) (28), the Harvey-Bradshaw Index (HBI) (29), and
the Modified Pouchitis Disease Activity Index (MPDAI) (30). All
the participants answered the questionnaires regarding medicine
or antibiotic usage, travel diarrhea/diarrhea in the last 3 months
before participating in the study. Patients or controls, who used
antibiotics or corticoides 3 months before the start of the study,
were excluded. Overall, 98% of the study group originated from
Denmark, while the last 2% were integrated Danish citizens of
other ethnicity.
The stool samples were stored at −80◦C and thawed before
processing. The laboratory staff was blinded to patient histories.
Ethics Statement
Permission for the study was obtained from the Regional Ethics
Committee for Copenhagen County Hospitals (Permission no.
KA-03019, Permission no. KA-20060159) and all participants
gave their informed written consent. Healthy controls were
recruited among students and volunteers. Patients and healthy
controls completed a questionnaire about their condition and
their medication. IBD patients were diagnosed according to
standardized criteria (29, 31).
DNA Extraction
DNA extraction was performed according to the instructions of
the manufacturer (Qiagen, DNA stool mini kit Denmark) with
the following modifications: 100mg fecal sample was mixed with
1.4ml ASL buffer in a 2-ml tube and vortexed until the sample
was thoroughly homogenized. Samples subsequently mixed with
0.2 g sterile zirconia/silica beads. Hereafter, the samples were
processed on a TissueLyser for 6min at 30Hz. Lysis was
completed at a temperature of 95◦ C for 5min. Finally, DNA was
extracted according to the instruction of the QIAamp DNA stool
MiniKit and eluted in 100 µl elution buffer provided in the kit.
PCR Amplification
TheV2-V3 region of the 16S rDNA gene (∼200 bp) was amplified
using the universal primer set HDA 1 position 338-357: (5′ACT
CCT ACG GGA GGC AGC AGT′3) and HDA 2 position 539–
561: (5′GTA TTA CCG CGG CTG CTG GCA C–′3) (32). The
forward primer, HDA 1, was at the 5′end labeled with GC clamp
(5′CGCCCGGGGCGCGCCCCGGGCGGGGCGGGGGCA
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CGGGGGG ′3). PCRs were performed in a total volume of 50µL
containing 20µL of 5 PRIMEMastermix, 0.8µMprimer HDA 1-
GC, 0.8µM primer HDA 2, 10 µL of DNA template and, finally,
4 µL RNase free water.
The PCR was performed using the following conditions:
preheating at 94◦C for 4min proceeded by 30 cycles of
denaturing at 94◦C for 30 s, annealing at 56◦C for 30 s, elongation
at 68◦C for 45 s, and finally a single step of 68◦C for 7min. The
PCR products were run on a 0.8% agarose gel.
Denaturing Gradient Gel Electrophoresis
PCR fragments were separated by Denaturing Gradient Gel
Electrophoresis (DGGE) with DCode System according to
the manufacturer’s instructions. Eight percent Polyacrylamide
(vol/vol) [ratio of acrylamid:bisacrylamide (37.5:1)] was diluted
in 0.5xTAE buffer with pH 8.0 using a gradient ranging from
35 to 65% [100% acrylamide corresponds to 7M urea and
40% (vol/vol) formamide] (33). Gels were cast using a gradient
maker and a pump with a flow speed of 5mL per minute.
After polymerization of the gel (2 h), a 3% stacking gel without
denaturing chemicals was cast, and an appropriate comb was
subsequently inserted and left for 30min for polymerization. Gels
were run at 60◦C for 16 h at a constant voltage of 70V in 0.5x TAE
buffer. After electrophoresis, gels were stained with GelRED for
45min and analyzed using an ultraviolet trans-illuminator.
Data Analyses
Analysis of the DGGEwas performed blinded using BioNumerics
version 7.5 (Applied Maths NV, Sint-Martens-Latem, Belgium).
After normalization, a band matching was performed with
a tolerance of 1% and an optimization of 1%. The results
from the automatic band matching were checked manually and
corrected where necessary. The similarity between profiles was
calculated with a Pearson correlation. A dendrogram was then
constructed with UPGMA. The reliability of the dendrogram
was determined with a cophenetic correlation coefficient. This
coefficient compares a similarity matrix derived from the
dendrogram with the actual similarity matrix. Reliably separated
branches have a high cophenetic correlation. For each profile,
the Shannon Diversity Index of diversity and Pielou’s species
evenness were calculated. Linear discriminant analysis (LDA)
was used to analyze differences within patient groups and
healthy persons. All statistical analyses were performed after
mean-based normalization using analysis of variance (Anova)
with post hoc test Bonferroni. The level of significance was set
at p ≤ 0.05.
RESULTS
DNA was extracted from fecal samples and analyzed by
DGGE. The individual bands each representing a bacterium
were analyzed in BioNumerics. The microbiota was correlated
to the diagnosis. Based on the Shannon Diversity Index,
UC patients with active and inactive disease had significant
lower bacterial diversity in comparison to healthy controls,
p < 0.05∗ (Figure 1A). When comparing the species evenness
using Pielou’s index, UC patients had decreased species evenness
FIGURE 1 | (A) Shannon Diversity Index for patients with active (UCA) and
inactive (UCI) Ulcerative colitis vs. healthy person/Control group shows
patients group (UCI and UCA) have a significantly decreased bacterial
abundance in comparison to controls group, p < 0.05* (B) Pielou index shows
significantly decreased bacterial evenness in the patient groups (UCI and UCA)
vs. controls, p < 0.05.
compared with healthy controls, p ≤ 0.05 (Figure 1B). No
such difference was found between UC patients with active and
inactive disease, respectively.
Not only a reduced number of bands (low bacterial diversity),
but also brighter bands (increased bacterial concentration),
were observed using DGGE profiles in UC patients compared
to healthy controls. When using cluster analysis (Figure 2A),
UC patients with (red) and without (blue) active disease were
separated from healthy controls (green). This was confirmed
by linear discriminant analysis (LDA; Figure 2B), where the
controls in the red circle were separated from patients
(Figures 2A,B).
Analysis of the bacterial diversity of CD patients with active
(CDA) and inactive (CDI) disease in comparison with controls
showed that CD patients with active disease had a significantly
lower ShannonDiversity Index in comparison to healthy persons,
p < 0.05∗ (Figure 3A). When comparing the species evenness
using Pielou’s index, no significant differences were found
between patient groups vs. control group/healthy persons, p <
0.083 (Figure 3B).
Cluster analysis (Figure 4A) showed that generally profiles
from CD patients with (CDA, red) active disease could be found
in the same cluster as other CDA profiles. The same was seen for
CDI and control group. However, many exceptions were found
and the clusters were not clearly delineated. This effect was seen
more clearly with LDA, where healthy controls (in green) shown
in the red circle, were separated from the patients (Figure 4B).
No separation could be observed in the CDA and CDI analysis.
In comparison to healthy persons and well-functioning pouch
patients (PI), diseased pouch patients (PA) had a significantly
decreased Shannon Diversity Index, p < 0.05 (Figure 5A). When
comparing the species evenness using Pielou’s evenness index,
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FIGURE 2 | (A) Cluster analysis of control group and patient groups with
active (UCA in red)/inactive (UCI in blue) ulcerative colitis. (B) LDA shows that
controls in green are mostly gathered in the red circle.
a lower evenness was found in the patient groups; however,
only the difference between controls and PI reached significance
p < 0.05 (Figure 5B).
FIGURE 3 | (A) Shannon Diversity Index for CD patients with active (CDA) and
inactive disease (CDI) vs. controls show CDA have significantly decreased
bacterial abundance in comparison to CDI and controls, p > 0.05*. (B) Pielou
index shows no significant differences in species evenness in patient groups
vs. controls (p < 0.083).
Cluster analysis (Figure 6A) showed that DGGE profiles
from diseased pouch patients (red) and well-functioning pouch
patients (blue) were more similar to profiles from other patients,
while healthy controls also clustered with other healthy controls
(green). However, the clusters were not clearly delineated. A
better separation could be seen by LDA, where the majority
of controls separated from the patients shown in red circle
(Figures 6A,B).
DISCUSSION
The pathogenesis of IBD is still not clear. However, during the
last decades, the main focus has been on an imbalance in the
intestinal microbiome in IBD patients that might cause or trigger
the disease activity. Next generation sequencing investigation of
the gut microbiome provides large amounts of data, which can
be difficult to interpret, and it is still quite costly. The advantages
of using DGGE (34) compared with next generation sequencing
is that DGGE detects highly prevalent (high concentration)
intestinal bacteria, while next generation sequencing is random
and detects all DNA. Sequencing is biased by the primer
annealing, and even small amounts of DNA will be amplified. In
this study, we investigated the intestinal microbiota in IBD using
16S rDNA PCR and DGGE enabling the discovery of overall
differences in intestinal bacteria community within different IBD
groups and controls. When discussing the concept of diversity of
a microbial community, the terms species evenness and richness
are used. Bacterial richness, also known as the Shannon diversity
index is a measurement of the total number of species in the
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FIGURE 4 | (A) Cluster Analysis of controls and patient groups with active
(CDA, in red) and inactive (CDI, in blue) Crohn’s disease shows the group
clustering in colors (B) LDA shows control in green are mostly separated in the
red ring, from CDA in red and CDI in blue.
community, while evenness expresses how evenly the individuals
in the community are distributed over the different species (35).
As the colon contains two-thirds of the total amount of bacteria
FIGURE 5 | (A) Shannon Diversity Index of pouch patient groups with active
(PA) and inactive disease (PI) and controls shows PA has significant decreased
bacterial diversity index in comparison to the PI and control group, p < 0.05.
The differences were not significant in PI, p-value = 0.06. (B) Species
evenness (Pielou index) was lower in the patient groups compared to the
healthy controls, however these differences were only significant in PI, p <
0.05.
in the human body (36), it is an exceptional environment,
and a perfect symbiosis plays a key role in colon health. UC
is localized in the colon and is linked to intestinal bacterial
dysbiosis and reduced biodiversity (37). This is also confirmed
in our study, where UC patients with and without active disease
had significantly reduced Shannon diversity indices and reduced
fecal bacterial evenness in comparison with healthy persons
(Figure 1). LDA and cluster analysis (Figure 2B) confirm this
result, showing a separation between UC patients and healthy
controls. Yet, the question of what triggers the disease activity
in UC patients remains. If bacteria in the colon are responsible,
what are the differences in the intestinal bacteria community
in the UC patients with and without active disease? As we see
an overall reduced biodiversity in UC patients, the flares of UC
might be triggered by the shift between the different bacterial
communities in UC patient. The studies using next generation
sequencing reveal that a reduced amount of F. praustnitzii (38)
and an increased number of Proteobacteriae (39, 40) might have
an effect on UC relapses. In order to restore the biodiversity,
fecal microbiota transplantation (FMT)was performed and it was
shown to be effective to promote remission in UC patients with
active disease, confirming the role of the colon microbiota in UC
(26).
CD is a chronic inflammatory condition that involves any
part of the gastrointestinal tract. Colonic CD has been identified
in 60% of the CD patients (41), which often present with
diarrhea and an aggressive course of the disease. Intestinal
dysbiosis is also linked to colonic CD, with increased prevalence
of Faecalibacterium (Firmicutes) and two unidentified genera
of Clostridiales and Ruminococceae (42), while ileal patients
have a higher prevalence of Proteobacteria compared to healthy
subjects. Our results show that CD patients with active
disease have a significantly reduced Shannon diversity index in
comparison with CD patients with inactive disease and healthy
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FIGURE 6 | (A) Cluster analysis for pouch patients with active (PA, in red) and
inactive (PI, in blue) disease shows controls (green) clustered mostly together.
(B) LDA graph shows most of controls in green are separated from PI in blue
and PA in red.
controls (Figure 3A). Decreased species evenness was found in
CD patients with and without active disease compared to healthy
persons; however, these differences were not significant, p= 0.08
(Figure 3B). Interestingly, a metanalysis performed on FMT in
CD, reveals that FMT promotes remission in only 60% of the
CD patients (43), as only 60% of the CD patients had colonic
CD (41). Reduced bacterial diversity in children with CD was
reported previously (40, 44, 45).
Ileal pouch-anal anastomosis is a surgical treatment choice for
the majority of UC patients, who fail medical treatment therapy,
with the advantage of re-establishment of gastrointestinal
continuity and improvement of the quality of life for these
patients. Studies show that 40% of patients with ileal pouch-
anal anastomosis develop pouchitis during the first year after
surgery (46). Furthermore, antibiotic and probiotic treatment
appears to be effective to diminish pouchitis (47). Evidence
suggests that an abnormal mucosal immune response to altered
microbiota in the pouch leads to acute chronic inflammation
(48). Our analysis of bacterial diversity in pouch patients in
comparison with healthy persons shows that diseased pouch
patients (PA) have a significant decreased microbial diversity
in comparison to well-functioning pouch patients and healthy
persons, p < 0.05 (Figure 5A). Reduced diversity was shown
in well-functioning pouch patients in comparison to healthy
controls; however, the differences are not significant (Figure 5A).
Additionally, our results reveal significantly decreased fecal
bacterial evenness in well-functioning pouch patients suggesting
that the microbiota in these patients is dominated by just a few
species. Maharshak et al. (49) show that pre-pouchititis patients
have significantly decreased intestinal bacterial diversity 1 year
before pouchitis in comparison to pouch patients, who did not
develop pouchitis. The possibility of subclinical inflammation 1
year before pouchitis was confirmed using histological scores,
endoscopics and fecal calprotectin (49). This study supports
our results showing that well-functioning pouch patients have
significantly decreased fecal bacterial evenness and reduced
Shannon diversity indices in comparison to healthy persons,
which was also confirmed by our LDA analysis (Figure 6B). It
could be speculated whether most of the well-functioning pouch
patients in our cohort are in the stage of pre-pouchitis, shown by
reduced intestinal bacteria evenness in these patients. Increased
relapses in pouch patients might be explained by the surgical
treatment where the pouch has a “colon like” function, which
creates a good environment for bacteria to overgrow and cause
infections. This supports the finding that FMT does not promote
remission in pouchitis patients (50) as antibiotics do.
Microbial colonization has an important effect on the
instruction and regulation of the immune system (51). Abnormal
communication between gut microbial communities and the
mucosal immune system has been identified as the core defect
that leads to chronic intestinal inflammation (52). Current
studies are focusing on restoring a healthy intestinal microbiota
using FMT and probiotics to treat the intestinal bacterial
dysbiosis. This might open new treatment opportunities for IBD
patients treated with immune suppressive medication or for
those where medical treatment therapy fails.
CONCLUSION
This study shows that UC patients with and without active
disease have significantly decreased intestinal bacterial diversity
and evenness in comparison to healthy persons. However, CD
patients and diseased pouch patients had significantly decreased
intestinal bacterial diversity, during the active disease compared
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to healthy persons, CD patients and well-functioning pouch
patients without active disease.
The well-functioning pouch patients had significantly
decreased species evenness in comparison to diseased pouch
patients and healthy persons.
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